MA53481A - Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde - Google Patents

Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde

Info

Publication number
MA53481A
MA53481A MA053481A MA53481A MA53481A MA 53481 A MA53481 A MA 53481A MA 053481 A MA053481 A MA 053481A MA 53481 A MA53481 A MA 53481A MA 53481 A MA53481 A MA 53481A
Authority
MA
Morocco
Prior art keywords
compositions
methods
rheumatoid arthritis
treating subjects
subjects
Prior art date
Application number
MA053481A
Other languages
English (en)
Inventor
Anita Boyapati
Neil Graham
Toshio Kimura
Jérôme Msihid
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA53481A publication Critical patent/MA53481A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
MA053481A 2018-08-29 2019-08-28 Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde MA53481A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862724212P 2018-08-29 2018-08-29
US201862747301P 2018-10-18 2018-10-18
US201962798697P 2019-01-30 2019-01-30
US201962824399P 2019-03-27 2019-03-27
US201962856431P 2019-06-03 2019-06-03
US201962858443P 2019-06-07 2019-06-07
EP19192387 2019-08-19

Publications (1)

Publication Number Publication Date
MA53481A true MA53481A (fr) 2021-07-07

Family

ID=67851236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053481A MA53481A (fr) 2018-08-29 2019-08-28 Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde

Country Status (16)

Country Link
US (2) US11319375B2 (fr)
EP (1) EP3843852A1 (fr)
JP (1) JP7504871B2 (fr)
KR (1) KR20210049871A (fr)
CN (1) CN112955222A (fr)
AU (1) AU2019329958A1 (fr)
BR (1) BR112021003206A2 (fr)
CA (1) CA3110891A1 (fr)
CL (1) CL2021000483A1 (fr)
IL (1) IL280824A (fr)
MA (1) MA53481A (fr)
MX (1) MX2021002422A (fr)
PH (1) PH12021550416A1 (fr)
SG (1) SG11202101674QA (fr)
TW (1) TW202026035A (fr)
WO (1) WO2020047029A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021281119A1 (en) * 2020-05-26 2023-02-02 Sanofi Biotechnology Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
KR20230031015A (ko) * 2021-08-26 2023-03-07 주식회사 이뮨메드 자가면역질환의 예방 또는 치료를 위한 항체의약품
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (fr) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Proteine du recepteur du facteur d'induction des cellules humaines b2
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP1681305A3 (fr) 1991-03-18 2008-02-27 New York University Anticorps monoclonaux et chimères contre le facteur humain de nécrose de tumeurs
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2123593C (fr) 1992-09-15 2000-03-14 Craig A. Smith Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
UA66757C2 (en) 1996-02-26 2004-06-15 Advanced Res & Tech Inst Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
EP1224189B1 (fr) 1999-10-07 2006-01-25 Eli Lilly And Company Derives de dihydroquinolone condenses permettant d'inhiber la mrp1
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
JP2006522811A (ja) 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
CA2565714C (fr) 2004-05-06 2014-12-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Processus et compositions pour le traitement de l'uveite
GEP20105059B (en) 2004-07-26 2010-08-10 Biogen Idec Inc Anti-cd154 antibodies
US7838638B2 (en) 2005-12-13 2010-11-23 Eli Lilly And Company Anti-IL-17 antibodies
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
FR2920033B1 (fr) 2007-08-13 2014-08-22 Snecma Turbomachine avec diffuseur
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP4885308B2 (ja) 2009-03-19 2012-02-29 中外製薬株式会社 改良された抗体分子を含有する製剤
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2011006273A1 (fr) * 2009-07-15 2011-01-20 Eva Kovacs-Benke Combinaison d'un antagoniste de l'interleukine-6 humaine et d'un antagoniste du récepteur de l'interleukine-6 humaine dans une thérapie contre des maladies tumorales
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN102883748A (zh) 2010-05-07 2013-01-16 爱克索马技术有限公司 治疗IL-1β相关状况的方法
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
CN103370081A (zh) 2011-02-03 2013-10-23 桑塔鲁斯股份有限公司 受试者的选择和治疗
TWI568888B (zh) 2011-09-15 2017-02-01 第諾拉工業公司 氣體擴散電極及其製法和電化電解池
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
EP3042202A1 (fr) * 2013-09-03 2016-07-13 Graham, L. Douglas Procédés de traitement de la polyarthrite rhumatoïde
US20160280782A1 (en) * 2013-11-22 2016-09-29 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
WO2015116852A1 (fr) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de la polyarthrite rhumatoïde par l'administration d'un anticorps anti il-6r
US20170252434A1 (en) 2014-09-16 2017-09-07 Sanofi Biotechnology Compositions for improving the health related quality of life of rheumatoid arthritis patients
CN108473583A (zh) 2015-11-03 2018-08-31 赛诺菲生物技术公司 用于治疗葡萄膜炎和黄斑水肿的包含il6r抗体的组合物及其使用方法
TWI819435B (zh) 2016-03-07 2023-10-21 法商賽諾菲生物技術公司 用於治療類風濕性關節炎之組成物及方法

Also Published As

Publication number Publication date
TW202026035A (zh) 2020-07-16
BR112021003206A2 (pt) 2021-05-25
US20200102395A1 (en) 2020-04-02
SG11202101674QA (en) 2021-03-30
US11319375B2 (en) 2022-05-03
KR20210049871A (ko) 2021-05-06
CN112955222A (zh) 2021-06-11
EP3843852A1 (fr) 2021-07-07
JP7504871B2 (ja) 2024-06-24
PH12021550416A1 (en) 2021-09-27
CL2021000483A1 (es) 2021-07-19
US20230059376A1 (en) 2023-02-23
WO2020047029A1 (fr) 2020-03-05
AU2019329958A1 (en) 2021-03-18
IL280824A (en) 2021-04-29
MX2021002422A (es) 2021-07-15
CA3110891A1 (fr) 2020-03-05
JP2022502350A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA50269A (fr) Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
MA43640A (fr) Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA41449A (fr) Polythérapies pour le traitement de cancers
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA53481A (fr) Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA48637A (fr) Polythérapies pour le traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer